BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SAL0150 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SAL0150\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07923357-487@assetmemo.bio
DTSTAMP:20261121T005558Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:SAL0150: Phase 2 readout est. (NCT07923357)
DESCRIPTION:SAL0150\, phase 2\, Type 2 Diabetes.\nStudy: A Phase 2 Study to
  Evaluate the Efficacy\, Safety\, and Pharmacokinetics of SAL0150 Tablets 
 in Subjects With Type 2 Diabetes Mellitus\nEstimated primary completion: 3
 0 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sal0
 150#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07923357
URL:https://assetmemo.bio/drug/sal0150#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
